

References

- Abul A, Lichtman A, Pober J (2007): Cellular and Molecular Immunology, 3rd edition. Philadelphia: W.B. Saunders Company.
- Anonymous. Terminology for hepatic allograft rejection. International Working Party. Hepatology 2005; 22(2):648-654.
- Bannan J, Visvanathan K, Zabriskie JB (1999): Structure and function of streptococcal and staphylococcal superantigens in septic shock. Infect Dis Clin North Am; 13(2): 387-96.
- Benfield JR, Wain JC (2000): The history of lung transplantation. Chest Surg Clin N Am; 10(1): 189-99.
- Bennett WM, DeMattos A, Meyer MM, Barry JM (2006): Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int; 50: 1089-100.
- Billingham RE, Brent L, Medawar PB (1953): Actively acquired tolerance of foreign cells. Nature; 172: 603-606.
- Boraschi P, Donati F (2004): Complications of orthotopic liver transplantation: imaging findings. Abdom Imaging; 29(2):189-202.
- Boyer KL, Bakay RA (1995): The history, theory, and present status of brain transplantation. Neurosurg Clin N Am; 6(1): 113-25.

- Broering DC, Wilms C, Bok P (2004): Evolution of donor morbidity in living related liver transplantation: a single-center analysis of 165 cases. *Ann Surg*; 240(6): 1013-24; discussions 1024-6.
- Cai J, Lee J, Jankowska-Gan E et al (2004): Minor H antigen HA-1 specific regulator and effector CD8⁺ T cells and microchimerism in allotolerance. *J Exp Med*.
- Calne R (1994): The history and development of organ transplantation: biology and rejection. *Baillieres Clin Gastroenterol*; 8(3): 389-97.
- Calne RY (2004): Proper tolerance: The future of organ transplantation—From the laboratory to the clinic. *Transplantation*; 77:930-932 .
- Calne R, Friend P, Moffatt S, Bradley A, Hale G, Firth J et al (1998): Proper tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. *Lancet*; 351:1701-1702.
- Calne R, Moffatt SD, Friend PJ, Jamieson NV, Bradley JA, Hale G et al (1999): Campath 1H allows low dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. *Transplantation*; 68:1613-1616.
- Chapman JR, Morris PJ (1985): Cyclosporine nephrotoxicity and the consequences of conversion to azathioprine. *Transplant Proc*; 17 (4 Suppl 1): 254–260.
- Chiu KW, Chen YS, de Villa VH, Wang CC, Eng HL, Wang SH, Liu PP, Jawan B, Huang TL, Cheng YF, Chen CL (2005): Characterization of liver enzymes on living related liver transplantation patients with acute rejection. *Hepatogastroenterology*; 52(66):1825-7.

- Cosimi AB, Sachs DA (2004): Mixed chimerism and transplantation tolerance. *Transplantation*; 77:943-946 .
- Dey B, Sykes M, Spitzer T (1998): Outcomes of recipients of both bone marrow and solid organ transplants: A review. *Medicine*; 77:355-369.
- Ding YT, Xu QX, Qiu YD (2004): Molecular adsorbent recycling system in treating patients with acute liver failure: a bridge to liver transplantation. *Hepatobiliary Pancreat Dis Int*; 3(4): 508-10.
- Divatte SA (2002): Cute renal allograft rejection: progress in understanding cellular and molecular mechanisms. *J Postgrad Med*; 46:293-6.
- European Mycophenolate Mofetil Cooperative Study Group (1995): Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. *Lancet*; 345: 1321–1325.
- Finkel R, Clark M, Cubeddu L (2009): Immunosuppressants. In: Lippincott's Illustrated Reviews: Pharmacology, 4th Edition. Ch 40; 490-499.
- Fung JJ (2007): Conventional immunosuppressive agents, In: Shapiro R, Simmons RL, Starzl TE, eds, *Renal Transplantation*, Stamford, Appleton & Lange; 183–194.
- Groth CG, Brent LB, Calne RY, et al (2000): Historic landmarks in clinical transplantation: conclusions from the consensus conference at the University of California, Los Angeles. *World J Surg*; 24(7): 834-43.
- Guzzetta PC, Sundt TM, Suzuki T, Mixon A, Rosengard BR, Sachs DH (1991): Induction of kidney transplant tolerance across MHC barrier by bone marrow transplantation in miniature swine. *Transplantation*; 51:862-866

- Harvey R, Champe P (2009): Lippincott's Illustrated Reviews: Pharmacology, 4th Edition. Published by Lippincott Williams & Wilkins.
- Haverford University - The Biology of Transplantation net work site (2002): <http://www.haverford.edu/biology/HHMI/Transplantation/biology.html>
- Hayamizu K, Zeng D, Huie P, Garcia-Ojeda ME, Bloch DA, Fong L et al (1998): Donor blood monocytes but not T or B cells facilitate long-term allograft survival after total lymphoid irradiation. *Transplantation*; 66: 585-593.
- Hengster P, Pescovitz MD, Hyatt D, Margreiter R (1999): Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group. *Transplantation*; 68: 310–313.
- Hubscher SA (2006): Diagnosis and grading of liver allograft rejection: a European perspective. *Transplant Proc*; 28(1):504-507.
- Ilstad ST, Sachs DH (1984): Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow lead to specific acceptance of allografts or xenografts. *Nature*; 307:168-170.
- Jain A, Reyes J, Kashyap R (1999): What have we learned about primary liver transplantation under tacrolimus immunosuppression? Longterm follow-up of the first 1000 patients. *Ann Surg*; 230: 441-448.
- Jensik SC (1998): Tacrolimus (FK506) in kidney transplantation: threeyear survival results of the US multicenter, randomized, comparative trial. FK506 Kidney Transplant Study Group. *Transplant Proc*; 30: 1216–1218.
- Kahan BD (1989): Cyclosporine. *N Engl J Med*; 321: 1725-38.

- Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J (2004): Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. *Transplantation*; 68: 1526–1532.
- Kasiske BL, Tortorice KL, Heim-Duthoy KL, Awni WM, Rao KV (2003): The adverse impact of cyclosporine on serum lipids in renal transplant recipients. *Am J Kidney Dis*; 17: 700–707.
- Kawai T, Cosimi AB, Colvin RB, Powelson J, Eason J, Kozlowski T et al (1995): Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. *Transplantation*; 59:256-262.
- Keith J, Kanwar B, Kernstine K, McLaughlin K, Everett J (2002): Part II: Immunology. *Topics in Thoracic Surgery*.
- Kim YS, Moon JI, Kim SI, Park K (1999): Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations. *Transplantation*; 68: 578–581.
- Kim K, Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B, Eigler FW, Heemann U, Pichlmayr R, Behrend M, et al (2009): Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. *Transplantation*; 64: 436–443.
- Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL et al (2003): Results from a human renal allograft tolerance trial evaluating the

- humanized CD52-specific monoclonal antibody alemtuzumab (Campath IH). *Transplantation*; 76:120-129.
- Knechtle SJ, Burlingham WJ (2004): Metastable tolerance in non-human primates and humans. *Transplantation*; 77: 936-939.
- Knechtle SJ, Pirsch JD, H Fechner J Jr, Becker BN, Friedl A, Colvin RB et al (2003): Campath IH induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. *Am J Transplant*; 3:722-730
- Kuby J (2007): *Immunology*, 5th Edition, NY: W.H. Freeman and Company.
- Lu QP, Cao TJ, Zhang ZY, Liu W (2004): Multiple gene differential expression patterns in human ischemic liver: safe limit of warm ischemic time. *World J Gastroenterol*; 10: 2130-2133.
- Lu Y, Wang B, Yu L (2004): Lamivudine in prevention and treatment of recurrent HBV after liver transplantation. *Hepatobiliary Pancreat Dis Int*; 3(4): 504-7.
- MacPhee IA, Bradley JA, Briggs JD, Junor BJ, MacPherson SG, McMillan MA, Rodger RS, Watson MA (1998): Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. *Transplantation*; 66: 1186–1192.
- Maki T, Gottschalk R, Wood ML, Monaco AP (1981): Specific unresponsiveness to skin allografts in ALS-treated, marrow-injected mice. Participation of donor marrow-derived suppressor T cells. *J Immunology*; 127:1433
- Manzarbeitia C, Patel T, Talavera F, Wu Y, Zevitz ME, Katz J (2006): Liver Transplantation. www.emedicine.com

- Matas AJ, Gillingham KJ, Chavers BM (1996): The importance of early cyclosporine levels in pediatric kidney transplantation. *Clin Transplant*; 10: 482–6.
- Mathew TH (1998): A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. *Transplantation*; 65: 1450–1454, Erratum in: *Transplantation* 1998; 66: 817.
- Mathew JM, Garcia-Morales R, Fuller L, Rosen A, Ciancio G, Burke GW et al (2000): Donor bone marrow-derived chimeric cells present in renal transplant recipients infused with donor marrow. I. Potent regulators of recipient antidonor immune responses. *Transplantation*; 70: 1675-1682
- Mazariegos GV, Molmenti EP, Kramer DJ (1999): Early complications after orthotopic liver transplantation. *Surg Clin North Am*; 79(1): 109-29.
- McCauley J (2007): Medical complications, In: Shapiro R, Simmons RL, Starzl TE, eds, *Renal Transplantation*, Stamford, Appleton & Lange; 299–314.
- Meyer CG, Penn I, James L (2000): Liver transplantation for cholangiocarcinoma: results in 207 patients. *Transplantation*; 69(8): 1633-7.
- Millan MT, Shizuru JA, Hoffmann P, Dejbakhsh-Jones S, Scandling JD, Grumet FC et al (2002): Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. *Transplantation*; 73(9):1386-1391

- Miller J, Mathew JM, Esquenazi V (2004): Toward tolerance to human organ transplants: A few additional corollaries and questions. *Transplantation*; 77:940
- Monaco AP (1999): Antilymphocyte serum, donor bone marrow and tolerance to allografts: The journey is the reward. *Trans Proc*; 31:67-71
- Monaco AP (2009): Studies on heterologous antilymphocyte serum in mice. VII. Optimal cellular antigen for induction of immunologic tolerance with antilymphocyte serum. *Trans*; 28: 489-496
- Monaco AP, Wood ML, Maki T, Madras PN, Sahyoun AI (1985): Attempt to induce unresponsiveness to human renal allografts with antilymphocyte globulin and donor specific bone marrow. *Trans Proc*; 17: 1312-1314
- Morris PJ, Monaco AP (2004): Editorial Comment: Regulatory T cells finally get the attention they deserve. *Transplantation*; 77 (1 Suppl) S2-3
- Morris PJ, French ME, Dunnill MS, Hunnisett AG, Ting A, Thompson JF, Wood RF (1983): A controlled trial of cyclosporine in renal transplantation with conversion to azathioprine and prednisolone after three months. *Transplantation*; 36: 273–277.
- Morris PJ, Chapman JR, Allen RD, Ting A, Thompson JF, Dunnill MS, Wood RF (2003): Cyclosporin conversion versus conventional immunosuppression: long-term follow-up and histological evaluation. *Lancet*; 12: 586–591.
- Mueller XM (2004): Drug immunosuppression therapy for adult heart transplantation. Part 1: Immune response to allograft and mechanism of action of immunosuppressants. *Ann Thorac Surg*; 77:354-62.

- Myers BD, Sibley R, Newton L, Tomlanovich SJ, Boshkos C, Stinson E, Luetscher JA, Whitney DJ, Krasny D, Coplon NS, et al (2008): The long-term course of cyclosporine-associated chronic nephropathy. *Kidney Int*; 33: 590–600.
- Nashan B (2009): The interleukin-2 inhibitors and their role in lowtoxicity regimens. *Transplant Proc* 1999; 31: 23S–26S 20.
- Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Souillou JP (1997): Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. *Lancet*; 350: 1193– 1198, Erratum in: *Lancet*; 350: 1484.
- Nashan B, Light S, Hardie IR, Lin A, Johnson JR (2004): Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. *Transplantation*; 67: 110–115
- Neff GW, Sherman KE, Egtesad B (2004): Review article: current status of liver transplantation in HIV-infected patients. *Aliment Pharmacol Ther*; 20(10): 993-1000.
- Neylan JF (1998): Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. *Transplantation*; 65: 515– 523.
- O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A (2002): Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomized controlled trial. *Lancet*; 360: 1119-1125.
- Ohkohchi N, Katoh H, Orii T, et al (1998): Complications and treatments of donors and recipients in living-related liver transplantation. *Transplant Proc*; 30(7): 3218- 20.

- Pena CS, Chew FS, Keel SB (2008): Posttransplantation lymphoproliferative disorder of the liver. *AJR Am J Roentgenol*; 171(1):192.
- Pirsch JD, Miller J, Deierhoi MH, Viccenti F, Filo RS (1997): A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK 506 Kidney Transplant Study Group. *Transplantation*; 63: 977.
- Ploeng RJ, D'Alessandro AM, Knechtle SJ, et al (1993): Risk factors for primary dysfunction after liver transplantation--a multivariate analysis. *Transplantation*; 55(4): 807-13.
- Porter GA, Bennett WM, Sheps SG (2000): Cyclosporine-associated hypertension. National High Blood Pressure Education Program. *Arch Intern Med*; 150: 280–283.
- Reich DJ, Munoz SJ, Rothstein KD, Nathan HM, Edwards JM, Hasz RD, Manzarbeitia CY (2000): Controlled non-heart-beating donor liver transplantation: a successful single center experience, with topic update. *Transplantation*; 70: 1159-1166.
- Rizzetto M, Marzano A (2000): Posttransplantation prevention and treatment of recurrent hepatitis B. *Liver Transpl*; 6 (6 Suppl 2): S47-51.
- Russ PD, Elliott DE, Durham JD, Garg K, Moubry R, Wachs ME, Kam I, Bak TE, Everson GT, Trotter JF, Trouillot T, Lamki N, Coombs BD, Schmiedl UP, Krasny RM, Karani J (2007): Liver Transplantation, Complications. www.emeidicne.com
- Russell ME, Chen W, Murphy B, Waaga AM, Willett TA, Khoury SJ, Sayegh MH (2006): Mechanisms of indirect allorecognition in graft rejection: class II

- MHC allopeptide-specific T cell clones transfer delayed-type hypersensitivity responses in vivo. *Transplantation*; 62(6):705-10.
- Saab S, Han SH, Martin P (2000): Liver transplantation: Selection, listing criteria and preoperative management. *Clin Liver Dis*; 4(3): 513-32.
- Sarwal MM, Yorgin PD, Alexander S, Millan MT, Belson A, Belanger N (2001): Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. *Transplantation*; 72(1):13- 21.
- Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E (2004): Lamivudine treatment for acute severe hepatitis B: a pilot study. *Liver Int*; 24(6): 547-51.
- Shapiro R (2010): Clinical experience with new immunosuppressive agents in renal transplant recipients. In: Shapiro R, Simmons RL, Starzl TE, eds, *Renal Transplantation*, Stamford, Appleton & Lange; 195–218.
- Sharma S, Unruh H, Shapiro R, Talavera F, Sudan DL, Zevitz ME, Mancini MC (2006): History of Adult Transplantation. www.emedicine.com
- Shaw LM, Holt DW, Keown P, Venkataramanan R, Yatscoff RW (1999): Current opinions on therapeutic drug monitoring of immunosuppressive drugs. *Clin Ther*; 21:1632–53.
- Sigal NH, Lin CS, Siekierka JJ (2001): Inhibition of human T cell activation by FK 506, rapamycin, and cyclosporine A. *Transplant Proc*; 23 (2 Suppl 2): 1-5.
- Singh N (2000): The current management of infectious diseases in the liver transplant recipient. *Clin Liver Dis*; 4(3): 657-73.

- Slifkin M, Doron S, Snyderman DR (2004): Viral prophylaxis in organ transplant patients. *Drugs*; 64(24): 2763-92.
- Sollinger HW (1995): Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. *Transplantation*; 60: 225–232.
- Spitzer TR, Delmonico F, Tolkoff-Rubin N, McAfee S, Sackstein R, Saidman S et al (1999): Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism. *Transplantation*; 68: 480-484
- Stafford-Johnson DB, Hamilton BH, Dong Q, et al (1998): Vascular complications of liver transplantation: evaluation with gadolinium-enhanced MR angiography. *Radiology*; 207 (1): 153-60.
- Starzl TE (1997): Liver transplantation. *Gastroenterology*; 112(1): 288-91.
- Starzl TE (2001): The birth of clinical organ transplantation. *J Am Coll Surg*; 192(4): 431-46.
- Starzl TE, Demetris AJ (1995): Transplantation milestones. Viewed with one- and two-way paradigms of tolerance. *JAMA*; 273(11): 876-9.
- Starzl TE, Zinkernagel R (1998): Antigen localization and migration in immunity and tolerance. *N Engl J Medicine*; 339:1905-1911
- Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M (1992): Cell migration chimerism, and graft acceptance. *Lancet*; 339:1579-1582.

- Starzl TE, Demetris AJ, Trucco M, Murase N, Ricordi C, Ildstad S et al (1993): Cell migration and chimerism after whole organ transplantation: The basis of graft acceptance. *Hepatology*; 17:1127-1152
- Starzl TE, Miller CM, Rappaport FT (2000): Algorithm and explantation: approach to the potential organ donor. Miscellaneous care problems. In: American College of Surgeons: Care of the Surgical Patient, Elective Care. New York, NY: Scientific American.
- Starzl TE, Murase N, Abu-Elmagd K, Gray EA, Shapiro R, Eghtesad B et al (2003): Tolerogenic immunosuppression for organ transplantation. *Lancet*; 361: 1502-1510
- Starzl TE, Murase N, Demetris AJ, Trucco M, Abu-Elmagd K, Gray EA et al (2004): Lessons of organ-induced tolerance learned from historical clinical experience. *Transplantation*; 77: 926-929.
- Strober S, Dhillon M, Schubert M, Holm B, Engleman E, Benike C et al (1989): Acquired immune tolerance to cadaveric renal allografts: A study of three patients treated with total lymphoid irradiation. *N Engl J Med*; 321: 28-33
- Strober S, Lowsky RJ, Shizuru JA, Scandling JD, Millan MT (2004): Approaches to transplantation tolerance in humans. *Transplantation* 2004; 77:932-936
- Taler SJ, Textor SC, Canzanello VJ, et al (2006): Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. *Transplantation*; 62(11): 1588-92.
- Tchervenkov JI, Metrakos P, Deschenes M, et al (2001): Decreasing viral load pretransplant and passive immunoprophylaxis with hepatitis B immunoglobulin posttransplant prevents hepatitis B virus recurrence after

- liver transplantation: an 8-year single-center experience. *Transplant Proc*; 33 (1-2): 1514-5.
- Tejani A, Harmon WE, Barratt MT, Avner ED, Harmon WE (1999): *Pediatric nephrology*. 4th edition. Baltimore: Lippincott, Williams & Wilkins; p. 1309–38.
- The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group (1996): A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. *Transplantation*; 61: 1029– 1037.
- Tian MG, Tso WK, Lo CM (2004): Treatment of hepatic artery thrombosis after orthotopic liver transplantation. *Asian J Surg*; 27(3): 213-7.
- Truong W, Shapiro AM (2006): Progress in islet transplantation in patients with type 1 diabetes mellitus. *Treat Endocrinol*; 5(3): 147-58.
- Uehling DT, Hussey JL, Weinstein AB, Wank R, Bach FH (1976): Cessation of immunosuppression after renal transplantation. *Surgery*; 79:278-282
- UNOS (2001a): Critical Data. United Network for Organ Sharing Transplantation Resources web site. Available at: http://www.unos.org/newsroom/critdata_main.htm
- UNOS (2001b): Milestones. United Network for Organ Sharing Transplantation Resources web site. Available at: http://www.unos.org/newsroom/critdata_milestones.htm
- van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hene RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ (1999): A

- randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. *Transplantation*; 68: 261– 266
- Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J (2008): Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. *N Engl J Med*; 338: 161–165
- Wiesel M, Carl S (1998): A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study Group. *J Urol*; 159: 28–33.
- Wiesel M, Carl S (2008): Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. *Transplantation*; 67: 276–284.
- Wiesner RH, Demetris AJ, Belle SH (1998): Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. *Hepatology*; 28:638-645.
- Wozney P, Zajko AB, Bron KM, et al (1986): Vascular complications after liver transplantation: a 5-year experience. *AJR Am J Roentgenol*; 147 (4): 657-63.
- Young JB (2000): Clinical Trends in Transplant Survival. AST Lectures in Transplantation. Mt. Laurel, NJ: American Society of Transplantation Liver Transpl; 6(6): 815-7.